CA2053911A1 - Proteines recombinantes de fusion anticorps-toxine - Google Patents

Proteines recombinantes de fusion anticorps-toxine

Info

Publication number
CA2053911A1
CA2053911A1 CA2053911A CA2053911A CA2053911A1 CA 2053911 A1 CA2053911 A1 CA 2053911A1 CA 2053911 A CA2053911 A CA 2053911A CA 2053911 A CA2053911 A CA 2053911A CA 2053911 A1 CA2053911 A1 CA 2053911A1
Authority
CA
Canada
Prior art keywords
toxin fusion
fusion protein
recombinant antibody
antibody toxin
unproved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2053911A
Other languages
English (en)
Other versions
CA2053911C (fr
Inventor
Ira H. Pastan
David Fitzgerald
Cary L. Queen
Thomas A. Waldmann
Vijay K. Chaudhary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
PDL Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2053911A1 publication Critical patent/CA2053911A1/fr
Application granted granted Critical
Publication of CA2053911C publication Critical patent/CA2053911C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des protéines recombinantes de fusion anticorps-toxine qui tuent de manière sélective des cellules porteuses d'antigènes ou de récepteurs appropriés. L'invention concerne également la construction et l'expression d'une protéine de fusion anticorps-toxine à chaîne unique, appelée anti-Tac (Fv)-PE40, le gène de fusion et la production de toxines améliorées utilisant PE.
CA002053911A 1989-04-21 1990-04-20 Proteines recombinantes de fusion anticorps-toxine Expired - Lifetime CA2053911C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34136189A 1989-04-21 1989-04-21
US341,361 1989-04-21
PCT/US1990/002097 WO1990012592A1 (fr) 1989-04-21 1990-04-20 Proteine recombinante de fusion anticorps-toxine

Publications (2)

Publication Number Publication Date
CA2053911A1 true CA2053911A1 (fr) 1990-10-22
CA2053911C CA2053911C (fr) 1999-11-02

Family

ID=23337235

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002053911A Expired - Lifetime CA2053911C (fr) 1989-04-21 1990-04-20 Proteines recombinantes de fusion anticorps-toxine

Country Status (10)

Country Link
EP (1) EP0469065B1 (fr)
JP (1) JPH0829101B2 (fr)
AT (1) ATE138688T1 (fr)
AU (1) AU641392B2 (fr)
CA (1) CA2053911C (fr)
DE (1) DE69027210T2 (fr)
DK (1) DK0469065T3 (fr)
ES (1) ES2091824T3 (fr)
IL (1) IL94159A0 (fr)
WO (1) WO1990012592A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631200B2 (en) * 1989-02-17 1992-11-19 Merck & Co., Inc. Production of modified pe40
EP0383599B1 (fr) * 1989-02-17 1996-02-07 Merck & Co. Inc. Agent anticancéreux protéique
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
CA2120153C (fr) * 1991-09-30 2006-06-06 Ira Pastan Immunotoxines recombinantes
JP3024311B2 (ja) 1991-10-03 2000-03-21 味の素株式会社 Ｉｌ−２受容体重鎖に結合するポリペプチド
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
CA2372813A1 (fr) * 1992-02-06 1993-08-19 L.L. Houston Proteine fixatrice biosynthetique pour marqueur du cancer
IL123294A0 (en) * 1995-10-19 1998-09-24 Bristol Myers Squibb Co Monoclonal antibody BR110 and uses thereof
IL116559A (en) * 1995-11-17 2005-11-20 Yissum Res Dev Co Chimeric protein consisting of a bacterial toxin and a myelin basic protein sequence
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
CN1244772A (zh) * 1996-10-23 2000-02-16 威克福雷大学 靶向性细胞毒性细胞
WO2008151819A2 (fr) 2007-06-15 2008-12-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Traitement de tumeurs à l'aide d'un anticorps anti-l1 spécifique
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
KR102554634B1 (ko) 2014-09-30 2023-07-11 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 L1cam에 결합하는 신규한 결합 분자 특히 항체(cd171)
WO2016146833A1 (fr) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarqueurs de résistance à la nad(+)-diphtamide adp-ribosyltransférase
EP3184547A1 (fr) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anticorps anti-tpbg et procédés d'utilisation
WO2018115485A1 (fr) 2016-12-22 2018-06-28 Pierfrancesco Tassone Anticorps monoclonal ciblant un épitope de cd43 unique associé au cancer sialoglycosilé

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE25197T1 (de) * 1982-05-12 1987-02-15 Harvard College Hybridproteinekodierende fusionierte gene, sie enthaltende klonierungsvektoren und deren verwendung.
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4867962A (en) * 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies
EP0383599B1 (fr) * 1989-02-17 1996-02-07 Merck & Co. Inc. Agent anticancéreux protéique

Also Published As

Publication number Publication date
AU5562790A (en) 1990-11-16
EP0469065A1 (fr) 1992-02-05
DK0469065T3 (da) 1996-07-15
DE69027210D1 (de) 1996-07-04
WO1990012592A1 (fr) 1990-11-01
JPH0829101B2 (ja) 1996-03-27
JPH04504363A (ja) 1992-08-06
AU641392B2 (en) 1993-09-23
IL94159A0 (en) 1991-01-31
EP0469065A4 (en) 1992-07-08
EP0469065B1 (fr) 1996-05-29
ATE138688T1 (de) 1996-06-15
DE69027210T2 (de) 1997-01-23
ES2091824T3 (es) 1996-11-16
CA2053911C (fr) 1999-11-02

Similar Documents

Publication Publication Date Title
CA2053911A1 (fr) Proteines recombinantes de fusion anticorps-toxine
DE59813875D1 (de) Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
TR199902426T2 (xx) Bitki b�ceklerinin kontrol�.
BG104149A (en) Interleukin-18-binding proteins, methods for their preparation and administration
NZ233642A (en) Linked hemoglobin subunits, preparation by genetic engineering and linker assay
DE69534778D1 (en) Cathepsin-02-protease
HK1012841A1 (en) Pharmaceutical composition for the treatment or prevention of amalignant tumor
DE68918867D1 (de) Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
AU1582495A (en) Recombinant baculovirus and use thereof in the production of monoclonal antibodies
ATE171596T1 (de) Neue gegen phtiraptera aktive bcillus thuringiensis isolate
DE69520088D1 (de) Interferon-gamma-induzierendes Polypeptid monoklonal Antikörper, und Zusammensetzung für Interferon-gamma gebunden Krankheiten
CA2210751A1 (fr) Anticorps monoclonaux anti-cd6 et ses utilisations
CA2160131A1 (fr) Nouvelles souches de bacillus thuringiensis et leurs proteines insecticides
AU8947791A (en) Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
AU2236795A (en) Afamin: a human serum albumin-like protein
CA2183546A1 (fr) Fibrinogene transgenique
FR2565985B1 (fr) Nouvelles substances biologiquement actives obtenues a partir de la caseine bovine, leur procede de preparation et les compositions qui les contiennent
ATE299182T1 (de) Polynukleotide und polypeptide aus pathogenen mycobakterien und deren verwendung als diagnostika, impfstoffe und als ziel der chemotherapie
ATE285474T1 (de) Haemophilus adhäsionsproteinen
CA2126182A1 (fr) Anticorps humanises reagissant avec le gpiib/iiia
CA2125486A1 (fr) Epitopes p1a1 et p1a2 de la proteine plaquettaire gpiiia, leur preparation et leur utilisation
HUP9801438A3 (en) Recombinant preduodenal lipases and polypeptide derivatives produced by plants, processes for obtaining them and their uses
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
CA2199403A1 (fr) Nouvelles proteines fixant la proteine kinase a (pka) et leur utilisation
CA2194032A1 (fr) Sequence d'adn fusionnee, proteine fusionnee exprimee par ladite sequence d'adn et methode d'expression de ladite proteine fusionnee

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry